MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer

By sjmartinez • October 11, 2023

Crowell PD, Giafaglione JM, Jones AE, Nunley NM, Hashimoto T, Delcourt AML, Petcherski A, Agrawal R, Bernard MJ, Diaz JA, Heering KY, Huang RR, Low JY, Matulionis N, Navone NM, Ye H, Zoubeidi A, Christofk HR, Rettig MB, Reiter RE, Haffner MC, Boutros PC, Shirihai OS, Divakaruni AS, Goldstein AS. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep. 2023 Oct 9;42(10):113221. doi: 10.1016/j.celrep.2023.113221. Epub ahead of print. PMID: 37815914.

Tags: Cancer, CP, Endocrinology, Metabolism, Publications

Productive infection of the retinal pigment epithelium by SARS-CoV-2: Initial effects and consideration of long-term consequences

Hultgren NW, Petcherski A, Torriano S, Komirisetty R, Sharma M, Zhou T, Burgess BL, Ngo J, Osto C, Shabane B, Shirihai OS, Kelesidis T, Williams[...]

Increasing Diversity in the Nutrition, Obesity, and Diabetes Biomedical Workforce: The BRIDGES Consortium

Newton RL Jr, Katzmarzyk PT, Duru OK, Lee A, Irwin A, Mangione CM, Morone NE, Ongeri EM, Shaikh SR, Stanford FC, Stanley TL, Truesdale KP;[...]

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]